9 Result(s)

Article

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

The activation of dendritic cells (DCs) is pivotal for generating antigen-specific T-cell responses to eradicate tumor cells. Hence, immunotherapies targeting this interplay are especially intriguing. Moreover...

Jessica Wenthe, Emma Eriksson, Ann-Charlotte Hellström… in Journal of Translational Medicine (2023)

Article

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor e...

Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsén… in Nature Communications (2021)

Article

Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients

An important aspect of end-of-life care is the place of death. A majority of cancer patients prefer home death to hospital death. At the same time, the actual location of death is often against patient’s last-...

Jonas Nilsson, Georg Holgersson, Gustav Ullenhag, Malin Holmgren… in BMC Palliative Care (2021)

Article

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in metastatic uveal melanoma. Thus, metastatic ...

Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro… in BMC Cancer (2019)

Article

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey Ager, Matthew Reilley, Courtney Nicholas… in Journal for ImmunoTherapy of Cancer (2016)

Article

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Cancer immunotherapy can be potentiated by conditioning regimens such as cyclophosphamide, which reduces the level of regulatory T cells (tregs). However, myeloid suppressive cells are still remaining. Accordi...

Emma Eriksson, Jessica Wenthe, Sandra Irenaeus… in Journal of Translational Medicine (2016)

Article

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immun...

Angelica Loskog, Aglaia Maleka, Sara Mangsbo, Emma Svensson… in British Journal of Cancer (2016)

Article

Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

Roger Olofsson Bagge, Lars Ny, Charlotta All-Ericsson, Malin Sternby Eilard… in Trials (2015)

Article

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with th...

Roger Olofsson, Lars Ny, Malin Sternby Eilard, Magnus Rizell, Christian Cahlin… in Trials (2014)